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Abstract
It is conventional strategy to treat highly malignant brain tumors initially with cytoreductive surgery
followed by adjuvant radio- and chemotherapy. However, in spite of all such efforts, the patients'
prognosis remains dismal since residual glioma cells continue to infiltrate adjacent parenchyma and
the tumors almost always recur. On the basis of a simple biomechanical conjecture that we have
introduced previously, we argue here that by affecting the 'volume-pressure' relationship and
minimizing surface tension of the remaining tumor cells, gross total resection may have an inductive
effect on the invasiveness of the tumor cells left behind. Potential implications for treatment
strategies are discussed.
Background
Malignant brain tumors such as gliomas expand through
proliferation and invasion within the confines of the bony
skull, hence in a mechanically constraint area. That is, the
brain tissue's mechanical 'reserve' rooms, i.e. the intersti-
tial space, the cerebrospinal fluid filled ventricles and the
vascular system can only temporarily compensate,
through fluid shifts, any sudden or even gradual increase
in intracranial pressure (ICP) as it relates to e.g. an intrac-
erebral hemorrhage or a tumor. Once the point of decom-
pensation is reached (Figure 1) any even miniscule
increase in volume will trigger a massive, life-threatening
increase in ICP [1] that generally leads to surgical inter-
vention in an attempt to resect some of this pressure-rais-
ing volume.
Standard treatment for highly aggressive gliomas (ana-
plastic astrocytomas and glioblastomas (GBM)) has there-
fore changed little over the years and still consists of gross
surgical resection followed by adjuvant radiotherapy and
chemotherapy (e.g., [2]). The problem is that the already
spatially disseminated tumor cannot be visualized at the
single cell level with current clinical imaging modalities,
let alone be removed completely. Hence, after a period of
temporary betterment, the tumor almost always returns,
primarily locally, i.e., at the surgical edge, in conjunction
with widespread tissue invasion that at some point pro-
hibits further cytoreductive therapy. Therefore, regardless
of any treatment, the grim outcome overall did not change
in decades with most GBM patients succumbing to the
disease within 1–2 years after diagnosis (e.g., [3]). New
approaches are therefore desperately needed and, as
always, the development of innovative strategies starts
with a better understanding of the current limitations.
Here, we discuss, from a pure theoretical and simple
mechanistic perspective, if the first line approach of surgi-
cal debulking has any impact on the characteristic inva-
sive behaviour of these cancer systems post-extirpation of
the tumor core.
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Hypothesis
Presentation
In vitro, invasive gliomas display finger-like invasive pat-
terns in three-dimensional extracellular matrix environ-
ments [4], not unlike the chain-like migration seen from
gliomas in vivo by following axonal fiber tracts and blood
vessels [5,6]. Such 'fingering' morphology is common in
other physical contexts as well: for instance, (i) when a
'crack' occurs in a solid specimen experiencing a point-like
internal breakage or, with a growing inclusion inside [7],
(ii) when a drop of liquid is injected in a more viscous
environment ('Hele-Shaw' effect), or (iii) when a liquid
drop impacts on a solid surface, causing the formation of
a fluid 'crown' ('Rayleigh' or 'Yarin-Weiss' capillary insta-
bility [8]). Detailed investigations of these models predict
the number N  of fingers which are expected to form
depending on the characteristics of the media. Notably,
under some very general assumptions, the number of
parameters to be accounted for predicting N is very low,
and can be reduced to the radius R of the 'drop' or of the
inclusion, the external pressure P which acts on it and
finally, the surface tension σ.
As previously proposed in [9], based on Eq. (1), a dimen-
sionless Invasion Parameter, IP, can be defined assuming
that invasion occurs (IP > 1) when N ≥ 1.
IP = PR/σ (2)
Here,  P  stands for the confining mechanical pressure
exerted by the microenvironment on the tumor, R for the
radius of the tumor, and σ for the tension at the tumor
surface. According to Eq. (2), invasive cell behaviour is to
be expected in all but for the case of IP < 1 (which implies
large tumor surface tension, small confining pressure and/
or small tumor radius values).
In the case of malignant gliomas, surgical debulking is
geared to reduce the tumor burden, hence R  should
decrease, which in turn would diminish the product PR
and result in an overall IP decline, if σ would to remain
constant. To be more specific, according to Schettini and
Walsh [10] the reduction of an intracranial balloon vol-
ume from 6 ml to 0.5 ml (i.e., of a factor of 12) would pro-
duce a reduction of the product PR, being P  the
intracranial pressure measured in the ipsilateral ventricle
of a factor ranging from 24 to 8.8 mmHg, i.e., roughly of
an order of magnitude. Such measurements, however, are
performed 'acutely', i.e., before compensatory mecha-
nisms, due to both the nonlinear viscoelastic behaviour of
the brain and circulatory autoregulation, are elicited.
Therefore, on a closer look, there are a few important cave-
ats:
• First, this 'volume-pressure' relationship or elastance
(and its inverse quantity, compliance) found for the
inflated epidural balloon in experimental settings should,
in reality, only hold for benign tumors that grow strictly
compressive and non-infiltrative in nature such as most
meningiomas [11]. In fact, Hase et al. [1] already com-
pared the ICP dynamics post-surgery for such meningi-
omas versus astrocytomas. The authors reported a higher
elastance for meningiomas (comparable to the solid line
in Figure 1), as compared to a lower elastance for malig-
nant astrocytomas (suggested as dotted line; see also Table
3 in [1]). That is, in astrocytomas, the same increase in
volume leads to a lesser increase in ICP. We argue that the
distinct infiltrative nature of these malignant tumors is
responsible for causing such 'favourable' mechanical con-
ditions for the neoplasm. (Gliomas for instance release
the neutotoxicity-inducing excitatory amino acid gluta-
mate [12] and produce matrix degrading enzymes or met-
alloproteinases [13] which together can impact and
disrupt surrounding tissue architecture, as seen on diffu-
sion tensor NMR [14,15]. None of the complicated bio-
chemical processes driving tumor progression is explicitly
included in our hypothesis here; rather, we focus on some
simple biomechanical aspects involved). Further, this
may delay the onset of purely pressure-related symptoms
which in turn can help explain the surprisingly large sizes
of some of these malignant tumors at the time of diagno-
sis. Conversely, surgically reducing tumor volume will
also lead to a relatively smaller rate of reduction in P.






Intracranial pressure-volume curve Figure 1
Intracranial pressure-volume curve. In the case of 
lower elastance (dotted line), the same increase in volume 
leads to a lower intracranial pressure increase than in the 
case of higher elastance (solid line) (from Hase et al. [1], with 
permission).Annals of Surgical Innovation and Research 2008, 2:1 http://www.asir-journal.com/content/2/1/1
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PR product may remain elevated and any sub-total resec-
tion (with a sizeable portion of R remaining) will only
add to this tendency.
• Secondly, by definition, gross total resection will aim to
remove the (on conventional imaging, now generally
nuclear magnetic resonance, or NMR, imaging) visible
surface of the tumor. The Laplace law should hold for the
resulting spherical shell and thus, σ should, if anything,
become very small postoperatively which in turn would
yield an excessive increase in IP for the remaining, already
disseminated cancer cells that remain below the current
imaging resolution. It is noteworthy in that context that
dexamethasone, a glucocorticosteroid often used peri-
operatively with the idea of treating tumoral edema for-
mation, has been shown to also increase the surface ten-
sion of the malignant astrocytoma cell lines U-87MG, U-
118MG and LN-229 [16]. One could therefore argue that
this effect may be one reason why peri-operative steroid
therapy is effective to some degree.
• And finally, adding the experimentally proven notion
that more invasive cells move faster on stiffer substrates
[17-19] to the aforementioned lower elastance of astrocy-
tomas post-extirpation also makes for an invasiveness-
promoting microenvironment for the remaining tumor
cell formations.
Implications
In Guiot et al. [9] we had deduced from Eq. (2) that
increasing σ (e.g., through stable E-cadherin transfection
as described already for prostate cancer cells in [20]), as
well as reducing P and R are the rather obvious, distinct
therapeutic goals. While this remains correct, what
deserves a more careful evaluation is their relationship par-
ticularly within the anatomic confines of a host organ
such as the brain. Surgical impact, while reducing R, tem-
porarily relieving P and thus at least subjectively improv-
ing the patient's symptoms can, for the reasons stated
above, potentially have detrimental inductive effects on
tumor invasion for the cells left behind, which are gener-
ally believed to significantly contribute to recurrence and
treatment failure (e.g., [21]). One could therefore argue,
that surgery fails to prevent if not even facilitates the tran-
sition of the tumor from a rather volumetric growth proc-
ess to a more diffusely expanding system, where
infiltrating glioma cells can switch to a proliferative phe-
notype and vice versa [22]; since such single cell dynamics
remain hidden largely below the current NMR imaging
threshold, this spatio-temporally propagating system now
provides the clinician with lesser if any macroscopic tar-
gets to go after, up until a sizeable tumor recurs. However,
suggesting not to operate would be irresponsible since the
severity of clinical symptoms all too often mandates rapid
surgical ICP relief and, not surprisingly, numerous studies
have shown that gross total resection improves the
patient's disease-free interval (e.g., [23]). That is, aside
from obtaining tissue for a histo-pathological confirma-
tion of tumor grade, the main biomechanical goal of any
surgical intervention is to approximate the flat part of Fig-
ure 1. Our conjecture only cautions about the standard
approach's potential side effects on the invasive cells left
behind and, in doing so, (1) confirms the indication for
pharmaceutical peri-operative ICP reduction, and (2)
reemphasizes the desperate need for effective anti-inva-
sive targeting modalities that are administered in conjunc-
tion with surgery (and conventional adjuvant regimen).
(Surgery of solid malignant tumors usually attempts to
excise larger margins in healthy tissue which, however, is
a limited option in the brain where any even minimal tis-
sue damage can add to the functional deficit already
caused by the tumor).
The former (1) refers also to avoiding an effective increase
in P, known as an 'ICP rebound phenomenon' that can
occur e.g. when the osmotic diuretic agent Mannitol
(administered to treat elevated ICP) extravasates into the
tissue which in turn can cause a reverse osmotic shift and
thus a detrimental raise in ICP [24]. Given that glucocor-
ticoids are still the treatment of choice, one would hope
for a renaissance of the pharmaceutical field that is geared
towards intracranial pressure reduction. The latter (2)
supports for instance further development of the recently
introduced anti-angiogenesis compounds. They are
designed to impact the nutrient supply system (by target-
ing integrin receptors [25] or related growth factors such
as VEGF [26]), thus supposedly help manage the PR
dynamics of any residual or recurrent tumor; in doing so,
they should also impact structural dissemination routes
for invasive glioma cells which are known to move along
the perivascular space amongst others [27]. Interestingly,
the perivascular space seems to be also a permissive loca-
tion of cancer stem cells [28] that have been implicated in
the development of treatment resistance [29]. Taken
together, while recent results raise some caution [30], so
far anti-angiogenetic drugs remain a promising strategy as
we have argued already in [31] on the basis of organ spe-
cific albeit limited carrying capacity.
In summary, following a primarily biomechanical conjec-
ture, the impact caused by undoubtedly necessary surgical
intervention may have unintended, inductive effects on
invasiveness of the glioma cells left behind. This empha-
sizes the need for pharmaceutical peri-operative ICP
reduction, and supports innovative strategies geared
directly towards targeting disseminated cells.
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